MECHANISM OF NON-GENOMIC ACTION OF VITAMIN D
MECHANISM OF NON-GENOMIC ACTION OF VITAMIN D
批准号:
2654541
负责人:
KEITH A HRUSKA
金额:
$20.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-02-01 至 2001-01-31
关键词:
1,25 dihydroxycholecalciferol antisense nucleic acid calcium flux calreticulin carbohydrate biosynthesis cell membrane confocal scanning microscopy cyclic nucleoside monophosphate endoplasmic reticulum enzyme activity hormone regulation /control mechanism inositol phosphates intermolecular interaction oligonucleotides osteoblasts protein kinase C receptor binding tissue /cell culture transfection vesicle /vacuole vitamin D receptors
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from investigator's abstract): There no longer
appears to be any question that the vitamin D metabolite, 1alpha,25-
dihydroxyvitamin D3 (1alpha,25-(OH)2D3, calcitriol or CT), and its
metabolic and synthetic analogs manifest nongenomic actions. Rapidly
emerging evidence indicates that the nongenomic action plays important
roles in controlling the mechanisms that underlie many diseases arising
from disturbances in calcium homeostasis (e.g., osteoporosis), cell
growth (breast carcinoma, psoriasis), cell differentiation and immune
responses (possibly AIDS). The recent advent of noncalcemic, synthetic
analogs has ushered in the realistic possibility of therapeutic use of
these synthetic agents for the treatment of the above-mentioned diseases.
The most prominent evidence for the nongenomic action of 1alpha,25-
(OH)2D3 is stimulation of an acute, transient increase in the
intracellular free calcium concentration ([Ca2+]I) and concomitant
production of inositol polyphosphates. These are the first measurable
manifestations that occur within one minute of cellular exposure to the
agents. These actions closely resemble those of membrane (cell surface)
receptor-agonist mediated mechanisms. However, the precise mechanisms
by which vitamin D analogs induce the acute change in [Ca2+]I are
unknown. The applicants' recent data demonstrate that the vitamin D
receptor (VDR) binds to both plasma membrane (PM) and endoplasmic
reticulum (ER). Furthermore, calreticulin (CRT) in the ER fraction is
a specific acceptance protein for VDR. Since these two membranes
constitute the major sites of [Ca2+]I control, the interaction between
VDR and the membranes, and the role of the interaction in [Ca2+]I
control must be clarified. Recent advances in cell biology (transfection
technology), synthesis of vitamin D analogs with different biological
properties and technologies related to the measurement of calcium fluxes
in living cells, as well as in isolated membrane vesicles, make it now
possible to logically investigate the problems at hand. Therefore, the
Specific Aims of the proposed studies are to: 1) analyze the interaction
of the VDR with the ER in order to elucidate the role of VDR/CT
interaction on Ca2+ release from the ER and to determine the function of
CRT in regulating intracellular Ca2+ stores; and 2) study the
interaction of the VDR with the PM in order to elucidate the role of
this interaction in acute Ca2+ influx stimulated by CT, and to identify
a PM-specific acceptance protein for VDR.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Advances in the Pathophysiology and Treatment of the CKD-MBD
-
批准号:10440482
-
项目类别:
-
资助金额:$42.59万
-
财政年份:2021
-
负责人:KEITH A HRUSKA
-
依托单位:
Novel Advances in the Pathophysiology and Treatment of the CKD-MBD
-
批准号:10298983
-
项目类别:
-
资助金额:$42.59万
-
财政年份:2021
-
负责人:KEITH A HRUSKA
-
依托单位:
Novel Advances in the Pathophysiology and Treatment of the CKD-MBD
-
批准号:10609908
-
项目类别:
-
资助金额:$42.59万
-
财政年份:2021
-
负责人:KEITH A HRUSKA
-
依托单位:
CARDIOVASCULAR RISK MECHANISMS IN CKD
-
批准号:8842624
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2012
-
负责人:KEITH A HRUSKA
-
依托单位:
CARDIOVASCULAR RISK MECHANISMS IN CKD
-
批准号:8372642
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2012
-
负责人:KEITH A HRUSKA
-
依托单位:
CARDIOVASCULAR RISK MECHANISMS IN CKD
-
批准号:8507216
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2012
-
负责人:KEITH A HRUSKA
-
依托单位:
CARDIOVASCULAR RISK MECHANISMS IN CKD
-
批准号:8668047
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2012
-
负责人:KEITH A HRUSKA
-
依托单位:
Novel Phosphate Binder: Effects on Hyperphosphatemia, Vascular Calcification & Bo
-
批准号:7912320
-
项目类别:
-
资助金额:$19.45万
-
财政年份:2010
-
负责人:KEITH A HRUSKA
-
依托单位:
The Role of BMP-7 in Chronic Kidney Disease
-
批准号:7283335
-
项目类别:
-
资助金额:$7.62万
-
财政年份:2006
-
负责人:KEITH A HRUSKA
-
依托单位:
RENAL OSTEODYSTROPHY AND VASCULAR CALCIFICATION
-
批准号:8503607
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2005
-
负责人:KEITH A HRUSKA
-
依托单位:
RENAL OSTEODYSTROPHY AND VASCULAR CALCIFICATION
-
批准号:8818891
-
项目类别:
-
资助金额:$34.31万
-
财政年份:2005
-
负责人:KEITH A HRUSKA
-
依托单位:
Renal Osteodystrophy and Vascular Calcification
-
批准号:7324128
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2005
-
负责人:KEITH A HRUSKA
-
依托单位:
RENAL OSTEODYSTROPHY AND VASCULAR CALCIFICATION
-
批准号:8281481
-
项目类别:
-
资助金额:$22.8万
-
财政年份:2005
-
负责人:KEITH A HRUSKA
-
依托单位:
RENAL OSTEODYSTROPHY AND VASCULAR CALCIFICATION
-
批准号:7921269
-
项目类别:
-
资助金额:$22.8万
-
财政年份:2005
-
负责人:KEITH A HRUSKA
-
依托单位:
Renal Osteodystrophy and Vascular Calcification
-
批准号:7036947
-
项目类别:
-
资助金额:$31.32万
-
财政年份:2005
-
负责人:KEITH A HRUSKA
-
依托单位:
Renal Osteodystrophy and Vascular Calcification
-
批准号:7162522
-
项目类别:
-
资助金额:$30.31万
-
财政年份:2005
-
负责人:KEITH A HRUSKA
-
依托单位:
Renal Osteodystrophy and Vascular Calcification
-
批准号:7538354
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2005
-
负责人:KEITH A HRUSKA
-
依托单位:
Pediatric Training Program in Chronic Kidney Diseases
-
批准号:6752541
-
项目类别:
-
资助金额:$11.48万
-
财政年份:2003
-
负责人:KEITH A HRUSKA
-
依托单位:
Pediatric Training Program in Chronic Kidney Diseases
-
批准号:7680466
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2003
-
负责人:KEITH A HRUSKA
-
依托单位:
Pediatric Training Program in Chronic Kidney Diseases
-
批准号:7241467
-
项目类别:
-
资助金额:$10.7万
-
财政年份:2003
-
负责人:KEITH A HRUSKA
-
依托单位:
海外基金